Today: 9 June 2026
HSBC share price near record highs: what to watch before the BoE and February results
2 February 2026
2 mins read

HSBC share price near record highs: what to watch before the BoE and February results

London, Feb 2, 2026, 07:51 GMT — Premarket

HSBC Holdings Plc (HSBA.L) shares approach Monday’s London Stock Exchange session close to their all-time high, having closed Friday 1.2% higher at 1,285.4 pence.

At the moment, traders are debating what will drive the stock — rates or guidance. UK bank shares have followed shifts in interest-rate expectations closely, and HSBC is no different.

This is crucial since net interest income—the difference between what a lender earns on loans and pays on deposits—usually takes a hit when rates drop. Bank valuations can shift sharply even on minor changes in the anticipated speed of rate cuts.

The Bank of England is set to keep its benchmark rate steady at 3.75% on Thursday, Reuters reported Monday, with officials likely to remain noncommittal about future cuts. “The timing of those rate cuts, however, is coming increasingly into question,” said Sanjay Raja, Deutsche Bank’s chief UK economist, as markets pulled back from expecting several reductions this year. Reuters

A softer domestic mood could offer some relief, albeit limited. The Institute of Directors reported its economic optimism index climbed to -48 in January from -66 in December. Still, chief economist Anna Leach noted businesses remain “not yet ready to increase either their capital or labour costs materially.” Reuters

HSBC’s update later this month will be closely watched for moves on return targets and capital, especially if the sector pushes for higher profitability goals. Sources told Reuters last week that HSBC, along with NatWest Group, Barclays, and Lloyds Banking Group, is expected to raise profit targets. HSBC is likely to boost its guidance on return on tangible equity (RoTE), a key profitability metric. “UK banks have benefited from earnings resilience lasting longer than initially expected,” said Peter Rothwell, head of banking at KPMG UK. Gary Greenwood at Shore Capital warned that government pressure for faster lending growth might lead to steeper loan pricing. Reuters

The rally has shaken up the upper echelons of the UK market. HSBC crossed the $300 billion mark in market value last week after hitting a record share price, edging it near AstraZeneca at the FTSE 100 summit.

The group has been making moves in Asia as well. HSBC confirmed its privatisation of Hang Seng Bank took effect on Jan. 26, with shares delisted from the Hong Kong Stock Exchange the next day. The bank expects to settle the scheme consideration by Feb. 4. Group CEO Georges Elhedery emphasized that “Hang Seng remains its own bank, with its own governance, brand, branch network and customer proposition.” HSBC

Chesnara has wrapped up the acquisition of HSBC Life (UK) Limited, a move initially unveiled last year. The company confirmed there have been no significant changes since the original announcement. CEO Steve Murray commented, “We are delighted to have completed the acquisition of HSBC Life UK.” TradingView

But the situation is a double-edged sword. Quicker rate cuts, intensified competition for deposits, or pressure to lend at slimmer margins might squeeze returns. And if growth falters, credit losses could hit hard.

The next key events are just around the corner: the BoE’s Feb. 5 rate decision and HSBC’s annual results due Feb. 25. Investors will watch closely for changes in return targets, buyback plans, and how HSBC plans to juggle cost-cutting with growth ambitions in Asia.

Stock Market Today

  • Docebo (TSX:DCBO) Valuation Story Shifts Amid Revised Earnings Guidance
    June 9, 2026, 10:40 AM EDT. Docebo's fair value remains at CA$35.97 despite updated financial models, reflecting a recalibration of valuation assumptions. Analysts highlight contrasting bullish views, citing a clear growth story backed by recent revenue guidance raising full-year 2026 estimates to US$271-275 million, against bearish concerns over limited analyst coverage and potential risks. The e-learning software provider forecast revenue of approximately US$65.4-65.6 million for Q1 2026, and US$66.7-66.9 million for Q2. At its Inspire 2026 event, Docebo unveiled a next-generation learning platform and key product updates, signaling strategic progress. Investors should monitor shifting assumptions and sector context amid evolving market narratives.

Latest articles

Autozi Shares Jump 400%, Filing Flags Risks for AZI

Autozi Shares Jump 400%, Filing Flags Risks for AZI

9 June 2026
Autozi Internet Technology shares soared over 400% to $5.69 in early Nasdaq trading after a 10-for-1 share consolidation slashed its share count to about 4.49 million, but the surge contrasts with a 63.1% revenue drop, 82.5% plunge in gross profit, and widened net loss, with the company warning of “substantial doubt” about its ability to continue as a going concern.
Redwire Shares Slip After $500 Million Stock Offering Filed

Redwire Shares Slip After $500 Million Stock Offering Filed

9 June 2026
Redwire Corp shares plunged 6.5% to $17.37 after launching a $500 million at-the-market stock program, raising dilution risks for investors as the company seeks flexible funding despite recent record backlog and strong revenue growth; the drop contrasted with gains at other space stocks, highlighting investor concern over potential share issuance.
Nuvalent Trades Close to $124 After GSK’s $10.6 Billion Offer

Nuvalent Trades Close to $124 After GSK’s $10.6 Billion Offer

9 June 2026
Nuvalent shares soared 38.9% to $122.93, just below GSK’s $124-a-share cash offer after the $10.6 billion buyout was announced, as investors bet on the deal closing with Nuvalent’s two lead lung-cancer drugs already under FDA review and a 40% premium to the last closing price driving the morning’s merger-arb trade.
Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
ST Engineering share price slips after NeuSAR-2 satellite plan and Singapore’s new space agency
Previous Story

ST Engineering share price slips after NeuSAR-2 satellite plan and Singapore’s new space agency

Samsung Electronics stock price dives 6% in Seoul selloff — what to watch before Tuesday’s open
Next Story

Samsung Electronics stock price dives 6% in Seoul selloff — what to watch before Tuesday’s open

Go toTop